May 30th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
selectION, Inc. declared the commencement of a Phase 1b study involving its leading candidate si-544 in adult individuals suffering from psoriasis vulgaris or psoriatic arthritis.
May 29th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.